Bruce Hausman
Analyst · Kathryn Thompson of Thompson Research Group. Your line is open
Thanks Jay, and good morning to everyone. Second quarter net sales were $358 million, up 26% over the prior year, including negative currency impact of $6 million or 210 basis points year-over-year. Organic sales were up 2%, which was in-line with our expectations. Looking at revenue in more detail, legacy sales in the Americas were up 1%, compared to the second quarter of last year and excluding the previously mentioned large customer order in 2018, sales in the Americas grew 5%. Legacy sales in EMEA grew 2% in local currency, but were down 4% in U.S. dollars, due to currency headwinds driven by the euro to USD and pound sterling to USD exchange rates versus prior. Legacy sales in Asia Pac were up 3% in local currency, compared to the second quarter of last year, but were down 2% in U.S. dollars largely due to the Australian dollar to USD exchange rate versus last year. In our Global Market segments, second quarter growth was driven by corporate office, public buildings, and healthcare. Second quarter gross profit margin was 38.8%, which included 1 million of Nora purchase accounting amortization. Adjusted gross profit margin was 39.1%, a 60-basis point improvement over gross profit margin in the prior year period. We were very pleased with the progress of our productivity initiative, the impact on our margin results, which improved sequentially throughout the quarter and positioned us well as we enter into the back half of 2019. SG&A expenses were $96 million Q2 or 26.8% of sales. We incurred unusually high legal expenses in the quarter of approximately 2.7 million related to the SEC matter. Separately, on the income tax line, we had a $3 million net reduction to tax expense in the second quarter related to a [indiscernible] liability adjustment. This item contributed to a favorably low tax rate in the second quarter. Now, looking at the operating income line, second quarter operating income was $43 million, compared with $34 million in the prior year period, excluding more purchase accounting in Q2 2019, Nora transaction-related expenses in Q2 2018. Adjusted operating income was $44 million in Q2 of 2019 compared to $37 million last year. In Q2, we recorded net income of $29 million, or $0.50 per diluted share, compared to net income of $21 million, or $0.35 per diluted share to last year. Adjusted net income was $30 million or $0.51 per diluted share in Q2 2019, compared to $25 million, or $0.42 per diluted share last year. Adjusted EBITDA was $57 million in the second quarter of 2019, compared to $48 million in the same period last year representing 12% growth in adjusted EBITDA. Moving to the balance sheet and cash flows. Our balance sheet and liquidity remain strong with [$217 million] of borrowing availability under our revolving credit facility at the end of the quarter. We also reduced inventory by [$13 million] sequentially from Q1 2019 to Q2 2019 as we continue to improve our working capital metrics. We also ended the quarter with 84 million of cash on hand and $672 million of gross debt, net debt, which is simply gross debt minus cash on hand was therefore 588 million at the end of the quarter. On a proforma basis, our trailing 12-month adjusted EBITDA is approximately 200 million as laid out in the reconciliation table on our earnings press release. Our leverage ratio, calculated as net debt to pro forma adjusted EBITDA was approximately 2.9. This result [indiscernible] by taking the 588 million as net debt divided by the 200 million of pro forma adjusted EBITDA over the trailing 12-months. These are all non-GAAP measures. And as a reminder, please refer to the reconciliation table in our press release to reconcile the GAAP to non-GAAP measures. Interest expense was $7 million in the second quarter, compared with $2 million in Q2 of last year. And the increase in interest expense was due to financing the Nora acquisition, which occurred in the third quarter of 2018. Depreciation and amortization was $11 million in Q2, compared to $9 million last year. And capital expenditures were in-line with expectations at $15 million in the second quarter, compared to $9 million last year as we continue to execute on our strategic objectives, including expanding manufacturing capabilities and productivity initiatives. In the second quarter, we also executed on the remaining 25 million of share repurchases available under our previously announced $100 million share repurchase program. And now, I would like to hand the call back to Jay to provide an update on our 2019 outlook.